 |
|
New potential drug target in tuberculosis
May 30, 2006Tuberculosis remains one of the deadliest threats to public health. Every year two million people die of the disease, which is caused by the microorganism Mycobacterium tuberculosis. Roughly one third of the world's population is infected and more and more bacterial strains have developed resistance to drugs. Researchers from the Hamburg Outstation of the European Molecular Biology Laboratory (EMBL) and the Max Planck Institute for Infection Biology (MPIIB) in Berlin have now obtained a structural image of a protein that the bacterium needs for survival in human cells. This image reveals features of the molecule that could be targeted by new antibiotic drugs. The results appear in this week's online issue of the Proceedings of the National Academy of Sciences (PNAS).
M. tuberculosis is dangerous because it hides and persists in the immune cells of our bodies. "It can only persist there because of the activity of key molecules," says Matthias Wilmanns, Head of EMBL Hamburg. "We are investigating the functions of tuberculosis proteins and determining their atomic structures, in hopes of finding weak points and new inhibitors."
A protein called LipB is essential for the organism because it activates cellular machines that drive the bacterium's metabolism. Stefan Kaufmann's department at the MPIIB has specialised in the biology of M. tuberculosis infection and its ability to survive in immune cells. They discovered that LipB is highly active in acutely infected cells, particularly in patients infected by multidrug-resistant forms of M. tuberculosis.
"In these cells we see a 70-fold increase in the production of LipB when compared to other cells," says Stefan Kaufmann, Director at the MPIIB. "This strongly indicates an involvement in pathogenesis and makes it a particularly interesting target where traditional drugs have lost their efficacy."
A structural picture of the protein—a kind of technical diagram of its building plan—has yielded important clues about its activity. Qingjun Ma from Wilmanns' group purified LipB and obtained crystals of the molecule. Using the high-energy synchrotron radiation beamlines at EMBL Hamburg, on the campus of the German Electron Synchrotron Radiation Facility (DESY), he created an atom-by-atom map of the protein's structure. A high-resolution picture of the active site of LipB bound to a lipid inhibitor helped to determine the function of the enzyme. In collaboration with EMBL's Proteomics Core Facility in Heidelberg and researchers from the University of Illinois (USA), the Hamburg group discovered how LipB attaches specific fatty acids onto other proteins.
"LipB is a very promising drug target," Wilmanns says, "because it belongs to a vital pathway. Unlike other organisms M. tuberculosis has no backup mechanism that could take over LipB's role. This means that an inhibitor blocking its active site would shut down key processes the bacterium needs to survive and replicate. This would be a very effective strategy for a drug."
The scientists will now search for compounds that can do so. At the same time, they are continuing to look for other proteins as drug targets. Wilmanns and his colleagues from various other institutes are now focusing on structures of molecules that help M. tuberculosis to persist in its dormant state and could become drug targets.
European Molecular Biology Laboratory
"In these cells we see a 70-fold increase in the production of LipB when compared to other cells," says Stefan Kaufmann, Director at the MPIIB. "This strongly indicates an involvement in pathogenesis and makes it a particularly interesting target where traditional drugs have lost their efficacy."
A structural picture of the protein—a kind of technical diagram of its building plan—has yielded important clues about its activity. Qingjun Ma from Wilmanns' group purified LipB and obtained crystals of the molecule. Using the high-energy synchrotron radiation beamlines at EMBL Hamburg, on the campus of the German Electron Synchrotron Radiation Facility (DESY), he created an atom-by-atom map of the protein's structure. A high-resolution picture of the active site of LipB bound to a lipid inhibitor helped to determine the function of the enzyme. In collaboration with EMBL's Proteomics Core Facility in Heidelberg and researchers from the University of Illinois (USA), the Hamburg group discovered how LipB attaches specific fatty acids onto other proteins.
"LipB is a very promising drug target," Wilmanns says, "because it belongs to a vital pathway. Unlike other organisms M. tuberculosis has no backup mechanism that could take over LipB's role. This means that an inhibitor blocking its active site would shut down key processes the bacterium needs to survive and replicate. This would be a very effective strategy for a drug."
The scientists will now search for compounds that can do so. At the same time, they are continuing to look for other proteins as drug targets. Wilmanns and his colleagues from various other institutes are now focusing on structures of molecules that help M. tuberculosis to persist in its dormant state and could become drug targets.
European Molecular Biology Laboratory
Tuberculosis Current Events and Tuberculosis News RSS'Deadly dozen' reports diseases worsened by climate change
Health experts from the Wildlife Conservation Society today released a report that lists 12 pathogens that could spread into new regions as a result of climate change, with potential impacts to both human and wildlife health and global economies.
Disease diagnosis in just 15 minutes
Testing for diseases such as cancer and multiple sclerosis could soon be as simple as using a pregnancy testing kit.
New way to make malaria medicine also first step in finding new antibiotics
University of Illinois microbiology professor William Metcalf and his collaborators have developed a way to mass-produce an antimalarial compound, potentially making the treatment of malaria less expensive.
How to differentiate abdominal tuberculosis from lymphomas?
The incidence of tuberculosis is increasing. Lymphadenopathy is the most common manifestation of abdominal tuberculosis and may, in up to 55% of cases without other evidence of abdominal involvement, be easily confused with lymphomas involving abdominal lymph nodes.
New insights could lead to a better pneumococcal vaccine
Discovery of a new, previously unknown mechanism of immunity suggests that there may be a better way to protect vulnerable children and adults against Streptococcus pneumoniae (pneumococcal) infection, say researchers at Children's Hospital Boston and Harvard School of Public Health (HSPH).
Tuberculosis drug shows promise against latent bacteria
A new study has shown that an investigational drug (R207910, currently in clinical trials against multi-drug resistant tuberculosis strains) is quite effective at killing latent bacteria. This revelation suggests that R207910 may lead to improved and shortened treatments for this globally prevalent disease.
Novel tuberculosis vaccine in Germany in clinical phase
For the first time in more than 80 years a promising live vaccine against tuberculosis has passed into the clinical phase in Germany: Since Monday of this week the new vaccine, which goes by the designation "VPM1002", has begun safety testing on volunteers in a Phase I clinical trial in Neuss, Germany.
New method to overcome multiple drug resistant diseases developed by Stanford researchers
Many drugs once considered Charles Atlases of the pharmaceutical realm have been reduced to the therapeutic equivalent of 97-pound weaklings as the diseases they once dispatched with ease have developed resistance to them.
India continues to progress in AIDS vaccine development efforts
A second Phase I AIDS vaccine clinical trial in India was successfully completed, the Indian Council of Medical Research, the National AIDS Control Organization and the International AIDS Vaccine Initiative announced. The results of the trial of an MVA-based AIDS vaccine candidate (TBC-M4), which was conducted in Chennai, indicated that the vaccine candidate had acceptable levels of safety and was well tolerated.
Extensively drug-resistant tuberculosis found in California
In the first statewide study of extensively drug-resistant tuberculosis (XDR TB) in the United States, California officials have identified 18 cases of the dangerous and difficult-to-treat disease between 1993 and 2006, and 77 cases that were one step away from XDR TB. The study appears in the August 15 issue of Clinical Infectious Diseases, now available online.
More Tuberculosis Current Events and Tuberculosis News Articles
 | The Bioarchaeology of Tuberculosis: A Global View on a Reemerging Disease by CHARLOTTE ROBERTS, JANE BUIKSTRA Though apparently in decline during the first half of the 20th century, tuberculosis has reawakened in both developed and developing countries, particularly among susceptible populations with immunodeficiency disorders.... |
 | Tuberculosis and the Politics of Exclusion: A History of Public Health and Migration to Los Angeles (Critical Issues in Health and Medicine) by Emily K. Abel Though notorious for its polluted air today, the city of Los Angeles once touted itself as a health resort. After the arrival of the transcontinental railroad in 1876, publicists launched a campaign to portray the city as the promised land, circulating countless stories of miraculous cures for the sick and debilitated. As more and more migrants poured in, however, a gap emerged between... |
 | The White Plague: Tuberculosis, Man, and Society by Rene J. Dubos |
 | Living in the Shadow of Death: Tuberculosis and the Social Experience of Illness in American History by Sheila M. Rothman Tuberculosis -- once the cause of as many as one in five deaths in the U.S. -- crossed all boundaries of class and gender, but the methods of treatment for men and women differed radically. While men were encouraged to go out to sea or to the open country, women were expected to stay at home, surrounded by family, to anticipate a lingering death. Several women, however, chose rather to head for... |
 | Captain of Death: The Story of Tuberculosis by Thomas M. Daniel The dramatic story of tuberculosis is told here in a straightforward and accessible style. It presents the stories of persons connected with the disease, either as victims, or as those who made contributions to our knowledge of it; in addition to these personal accounts, the book unfolds the history and explains the pathogenesis of TB. The re-emergence of tuberculosis as a major American public... |
 | Consumed in the City: Observing Tuberculosis at Century's End by Paul Joseph Draus As a public health field worker assigned to control tuberculosis in New York and Chicago in the 1990s, Paul Draus encountered the horrible effects of tuberculosis resurgence in urban areas, and the intersections of disease, blight, and poverty. Consumed in the City grows out of his experiences and offers a persuasive case for thinking about—and treating—tuberculosis as an inseparable... |
 | Tuberculosis Pearls by Neil W. Schluger, Timothy J., M.D. Harkin New York University, New York City. Handbook of 75 clinical case presentations in tuberculosis, with diagnosis, one-page discussion, and pearls. For residents and medical students. Halftone illustrations. DNLM: Tuberculosis, Pulmonary - diagnosis - case... |
 | The Making of a Social Disease: Tuberculosis in Nineteenth-Century France by David S. Barnes In this first English-language study of popular and scientific responses to tuberculosis in nineteenth-century France, David Barnes provides a much-needed historical perspective on a disease that is making an alarming comeback in the United States and Europe. Barnes argues that French perceptions of the disease--ranging from the early romantic image of a consumptive woman to the later view of a... |
 | Clinical Tuberculosis (A Hodder Arnold Publication) by Peter D Davies, Peeter Barnes, Stephen B Gordon Clinical Tuberculosis remains an indispensable resource for respiratory physicians, infectious disease specialists, public health workers and other individuals involved in the management and control of tuberculosis worldwide. This established reference is a comprehensive accoutn of tuberculosis, providing up-to-date and authoritative information on all aspects of the disease. It gives practical... |
 | Contagion and Confinement: Controlling Tuberculosis along the Skid Road by Barron H. Lerner Most historians of tuberculosis have focused on the sanatorium era of the early twentieth century, losing interest in the disease with the discovery of curative antibiotics in the 1940s. In Contagion and Confinement, Barron H. Lerner offers the first in-depth look at the history of tuberculosis control in the antibiotic era, providing a vital account of this neglected chapter in the history of... |
| © 2008 BrightSurf.com |